BHVN vs. VTRS, UTHR, RDY, SRPT, CTLT, ROIV, ELAN, LEGN, CERE, and ASND
Should you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Viatris (NASDAQ:VTRS) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment.
79.9% of Viatris shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 16.0% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Viatris has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Biohaven received 350 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 65.43% of users gave Biohaven an outperform vote while only 35.59% of users gave Viatris an outperform vote.
Viatris has higher revenue and earnings than Biohaven. Viatris is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Viatris currently has a consensus target price of $11.00, indicating a potential upside of 6.69%. Biohaven has a consensus target price of $51.63, indicating a potential upside of 55.64%. Given Viatris' stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than Viatris.
Biohaven has a net margin of 0.00% compared to Biohaven's net margin of -0.37%. Biohaven's return on equity of 16.63% beat Viatris' return on equity.
In the previous week, Biohaven had 4 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Biohaven and 5 mentions for Viatris. Viatris' average media sentiment score of 0.63 beat Biohaven's score of 0.29 indicating that Biohaven is being referred to more favorably in the news media.
Summary
Biohaven beats Viatris on 13 of the 18 factors compared between the two stocks.
Get Biohaven News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biohaven Competitors List
Related Companies and Tools
